SARS-CoV-2 Infection in Multiple Sclerosis
Results of the Spanish Neurology Society Registry
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received January 5, 2021
- Accepted in final form April 12, 2021
- First Published June 24, 2021.
Author Disclosures
- Georgina Arrambide, MD, PhD (garrambide{at}cem-cat.org),
- Miguel Ángel Llaneza-González, MD, PhD (miguelllaneza{at}hotmail.com),
- Lucienne Costa-Frossard França, MD (lufrossard{at}yahoo.es),
- Virginia Meca-Lallana, MD (virmeca{at}hotmail.com),
- Eva Fernández- Díaz, MD (evafdezdiaz{at}gmail.com),
- Irene Moreno-Torres, MD, PhD (irene.morenot{at}quironsalud.es),
- Jose Manuel García-Domínguez, PhD (jose_garciadom{at}hotmail.com),
- Gloria Ortega-Suero, MD (gloria271187{at}hotmail.com),
- Lucía Ayuso-Peralta, MD (lucia.ayuso{at}salud.madrid.org),
- Mayra Gómez-Moreno, PhD (mayragomezmoreno{at}yahoo.es),
- Javier J. Sotoca-Fernández, MD (jsotoca{at}mutuaterrassa.cat),
- Ana Belén Caminero-Rodríguez, MD (caminero.nrl{at}gmail.com),
- Luis A. Rodríguez de Antonio, MD (rodriguezdeantonio{at}yahoo.es),
- Marcial Corujo-Suárez, MD (marcial.corujo{at}ssib.es),
- María A. Otano-Martínez, MD (maria.otano.martinez{at}navarra.es),
- Francisco Carlos Pérez-Miralles, PhD (miralles_neuro{at}hotmail.com),
- Virginia Reyes-Garrido, MD (virginiareyesgarrido{at}gmail.com),
- Teresa Ayuso-Blanco, MD (tayusob{at}yahoo.es),
- José Jesús Balseiro-Gómez, MD (jbalseirogomez{at}gmail.com),
- Mercedes Muñoz-Pasadas, MD (mmpasadas{at}gmail.com),
- Inmaculada Pérez-Molina, PhD (inmapemo{at}gmail.com),
- Carmen Arnal-García, MD (tmearmen{at}hotmail.com),
- Ángela Domingo-Santos, MD (gela_yo{at}hotmail.com),
- Cristina Guijarro-Castro, MD, PhD (cristina.guijarro{at}sen.es),
- Cristina Íñiguez-Martínez, MD, PhD (cinniguez{at}salud.aragon.es),
- Nieves Téllez Lara, PhD (tellezlara{at}gmail.com),
- Fernando Castellanos-Pinedo, MD (fer.castellanosp{at}gmail.com),
- Tamara Castillo-Triviño, MD (tamaracastillo.tri{at}gmail.com),
- Debora María Cerdán-Santacruz, PhD (deboracerdan{at}hotmail.com),
- Ángel Pérez-Sempere, MD (aperezs{at}mac.com),
- Berta Sebastián Torres, MD (neube78{at}gmail.com),
- Amaya Álvarez de Arcaya, MD (amaya.alvarezdearcaya{at}gmail.com),
- Eva Costa-Arpín, PhD (costaarpin{at}yahoo.es),
- Eduardo Durán-Ferreras, PhD (eduardoduranferreras{at}gmail.com),
- Marta Fragoso-Martínez, MD (mfragosom{at}gmail.com),
- Montserrat González-Platas, MD, PhD (montserrat.gonzalezplatas{at}gmail.com),
- Lamberto Landete Pascual, PhD (lamberto676{at}gmail.com),
- Jorge Millán-Pascual, PhD (jorge.millan.pascual{at}gmail.com),
- Celia Oreja-Guevara, MD, PhD (orejacbn{at}gmail.com) and
- José E. Meca-Lallana, MD, PhD
- Georgina Arrambide, MD, PhD (garrambide{at}cem-cat.org),
(1) Sanofi advisory board on alemtuzumab and BTK inhibitors. (2) Merck advisory board on evobrutinib. (3) Roche advisory board on satralizumab.
NONE
(1) Speaking honoraria from Sanofi. (2) Travel and speaking honoraria from Stendhal. (3) Speaking honoraria from Merck. (4) Travel expenses for scientific meetings from Novartis. (5) Travel expenses for scientific meetings from Roche. (6) Travel expenses for scientific meetings from ECTRIMS.
(1) Frontiers in Neurology guest editor for Research Topic: Prognostic and Predictive Factors in Multiple Sclerosis and Related Disorders, 2020-2021
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Commercial entity: Novartis.
(1) Instituto de Salud Carlos III, ayudas de investigación en salud, FIS number PI19/01590, principal investigator, 2019-2022
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Miguel Ángel Llaneza-González, MD, PhD (miguelllaneza{at}hotmail.com),
BMSBiogenBayerMerckNovartisTEVARocheAlmirallSanofi Genzyme
NONE
BMSBiogenBayerMerckNovartisTEVARocheAlmirallSanofi Genzyme
NONE
NONE
NONE
NONE
BMSBiogenBayerMerckNovartisTEVARocheAlmirallSanofi Genzyme
BMSBiogenBayerMerckNovartisTEVARocheAlmirallSanofi Genzyme
NONE
NONE
MerckTEVASanofi Genzyme
NONE
Neurology Spanish Society
Neurology Spanish Society
NONE
NONE
NONE
NONE
NONE
NONE
- Lucienne Costa-Frossard França, MD (lufrossard{at}yahoo.es),
received payment for giving conferences, or travel expenses or research grants from Merck-Serono, Biogen, Sanofi-Genzyme, Roche, Bayer and Novartis. The remaining authors declare no conflicts of interest.
NONE
received payment for giving conferences, or travel expenses or research grants from Merck-Serono, Biogen, Sanofi-Genzyme, Roche, Bayer and Novartis. The remaining authors declare no conflicts of interest.
Editorial Board Member in American Journal of Psychiatry and Neuroscience
NONE
NONE
NONE
received payment for giving conferences, or travel expenses or research grants from Merck-Serono, Biogen, Sanofi-Genzyme, Roche, Bayer and Novartis. The remaining authors declare no conflicts of interest.
received payment for giving conferences, or travel expenses or research grants from Merck-Serono, Biogen, Sanofi-Genzyme, Roche, Bayer and Novartis. The remaining authors declare no conflicts of interest.
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Virginia Meca-Lallana, MD (virmeca{at}hotmail.com),
scientific advisory boards for Genzyme and Roche, and has received speaker honoraria from Sanofi-Aventis, Merck-Serono, Teva Pharmaceutical Industries Ltd, Novartis, Biogen Idec and Terumo.
NONE
Genzyme, Sanofi-Aventis, Merck-Serono, Teva Pharmaceutical Industries Ltd, Novartis, Biogen Idec and Terumo.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Eva Fernández- Díaz, MD (evafdezdiaz{at}gmail.com),
(1) Sanofi Genzyme(2) Merck S.L.
NONE
(1) Sanofi Genzyme, speaker honoraria (2) Merck S.L., speaker honoraria(3) Roche, speaker honoraria(4) Biogen , speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Irene Moreno-Torres, MD, PhD (irene.morenot{at}quironsalud.es),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Jose Manuel García-Domínguez, PhD (jose_garciadom{at}hotmail.com),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Gloria Ortega-Suero, MD (gloria271187{at}hotmail.com),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Lucía Ayuso-Peralta, MD (lucia.ayuso{at}salud.madrid.org),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Mayra Gómez-Moreno, PhD (mayragomezmoreno{at}yahoo.es),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Javier J. Sotoca-Fernández, MD (jsotoca{at}mutuaterrassa.cat),
None
NONE
I have received travel or speaker honoraria from Almirall, Bayer, Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, Teva.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Ana Belén Caminero-Rodríguez, MD (caminero.nrl{at}gmail.com),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Luis A. Rodríguez de Antonio, MD (rodriguezdeantonio{at}yahoo.es),
(1) Sanofi Aventis.
NONE
(1)Biogen Idec, travel grant.(2)Novartis, travel grant.(3)Almirall, travel grant, speaker honoraria.(4)Sanofi Aventis, travel grant, speaker honoraria.(5)Roche, speaker honoraria.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Marcial Corujo-Suárez, MD (marcial.corujo{at}ssib.es),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- María A. Otano-Martínez, MD (maria.otano.martinez{at}navarra.es),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Francisco Carlos Pérez-Miralles, PhD (miralles_neuro{at}hotmail.com),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
Dr. Francisco Perez-Miralles has received speaking honoraria from Almirall, Biogen Idec, Genzyme, Novartis, Sanofi-Aventis, and Teva.
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Virginia Reyes-Garrido, MD (virginiareyesgarrido{at}gmail.com),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Teresa Ayuso-Blanco, MD (tayusob{at}yahoo.es),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- José Jesús Balseiro-Gómez, MD (jbalseirogomez{at}gmail.com),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Mercedes Muñoz-Pasadas, MD (mmpasadas{at}gmail.com),
None
NONE
Sanofy-genzyme 437,78 e
NONE
NONE
NONE
NONE
NONE
NONE
Financiacion cursos formacion online de Teva, Sanofy-Genzyme, Biogen
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Inmaculada Pérez-Molina, PhD (inmapemo{at}gmail.com),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Carmen Arnal-García, MD (tmearmen{at}hotmail.com),
(1) BIOGEN (2) ROCHE (3) MERCK (4) TEVA (5) NOVARTIS (6) ALMIRALL
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Ángela Domingo-Santos, MD (gela_yo{at}hotmail.com),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Cristina Guijarro-Castro, MD, PhD (cristina.guijarro{at}sen.es),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Cristina Íñiguez-Martínez, MD, PhD (cinniguez{at}salud.aragon.es),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Nieves Téllez Lara, PhD (tellezlara{at}gmail.com),
Dr Tellez received honoraria from serving on advisory boards of MerckSerono, Novartis farmaceurica and Bristol Myers.
NONE
Dr Tellez receives revenue as speaker honoraria concept from Bayer Schering Pharma, Biogen Idec, MerckSerono, Novartis farmaceurica, Sanofi, Teva Parmaceuticals, Roche Pharma and Bristol Myers.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Dr Tellez Has received research support from Roche Pharma
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Fernando Castellanos-Pinedo, MD (fer.castellanosp{at}gmail.com),
(1) Roche Farma, S.A.
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Tamara Castillo-Triviño, MD (tamaracastillo.tri{at}gmail.com),
(1)Almirall (2)Biogen (3)Merck (4)Novartis (5)Roche (6)Sanofi-Genzyme.
NONE
(1)Almirall (2)Biogen (3)Merck (4)Novartis (5)Roche (6)Sanofi-Genzyme (7)Teva.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Department of Health, Basque Country Government, #2018111038, PI, 2018-2021
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Debora María Cerdán-Santacruz, PhD (deboracerdan{at}hotmail.com),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Ángel Pérez-Sempere, MD (aperezs{at}mac.com),
AP Sempere has received personal compensation for consulting or serving on a scientific advisory board with Biogen Idec, Merck Serono, Novartis and Roche
NONE
AP Sempere has received speaker honoraria from Almirall, Biogen Idec, Bayer Schering Pharma, Merck Serono, Novartis, Roche, Sanofi-Aventis, and Teva
AP Sempere served as a editor of Revista de Neurologia, 2005-2007
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Berta Sebastián Torres, MD (neube78{at}gmail.com),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Amaya Álvarez de Arcaya, MD (amaya.alvarezdearcaya{at}gmail.com),
None
NONE
speaker honoraria from Biogen Idec, Genzyme, Merck-Serono and Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Eva Costa-Arpín, PhD (costaarpin{at}yahoo.es),
(1) Biogen (2) Genzyme (3) Roche
NONE
(1) Biogen (2) Genzyme (3) Roche (4) Merck Serono (5) Novartis (6) Bial
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Eduardo Durán-Ferreras, PhD (eduardoduranferreras{at}gmail.com),
Biogen, Genzyme, Roche, Novartis, Merck
NONE
Biogen, Roche, Teva, Almirall, Merck, Genzyme, Novartis
NONE
NONE
NONE
NONE
NONE
Biogen, Novartis, Genzyme, Almirall, Teva, Roche, Merck
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Marta Fragoso-Martínez, MD (mfragosom{at}gmail.com),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Montserrat González-Platas, MD, PhD (montserrat.gonzalezplatas{at}gmail.com),
Commercial:Sanofi-Genzyme, Novartis, Roche and Merck, honorarium
NONE
Commercial:Sanofi-Genzyme, Novartis, Roche and Merck, honorarium
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Lamberto Landete Pascual, PhD (lamberto676{at}gmail.com),
I received fees for advisories and educational activities from. BiogenIdec Merck Novartis Sanofi TEVA Mylan Almirall Roche Bayer
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I received fees for advisories and educational activities from. BiogenIdec Merck Novartis Sanofi TEVA Mylan Almirall Roche Bayer
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jorge Millán-Pascual, PhD (jorge.millan.pascual{at}gmail.com),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Celia Oreja-Guevara, MD, PhD (orejacbn{at}gmail.com) and
Biogen Idec (1), Sanofi-Genzyme(1), Merck-Serono (1), Roche (1), Celgene(1) and Novartis(1)
NONE
(1) Speaker honoraria by Sanofi-Genzyme (1), Merck-Serono (1),Celgene-BMS (1), Biogen (1),Teva (1),Roche(1) and Novartis(1)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- José E. Meca-Lallana, MD, PhD
Dr. Jose E Meca-Lallana has received compensation for consulting services from Biogen-Idec, Bristol-Meyers-Squibb, Merck-Serono, Sanofi-Aventis, Roche and Teva Pharmaceutical Industries Ltd
NONE
Dr. Jose E Meca-Lallana has received speaker honoraria from Almirall, Biogen-Idec, Bristol-Meyers-Squibb, Merck-Serono, Novartis, Roche, Sanofi-Aventis and Teva Pharmaceutical Industries Ltd.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- From the Centro de Esclerosis Múltiple de Cataluña (G.A.), (Cemcat), Instituto de Investigación Vall d’Hebron, Hospital Universitario Vall d'Hebron, Universidad Autónoma de Barcelona; Complejo Hospitalario Universitario de Ferrol (M.Á.L.-G.); Hospital Universitario Ramón y Cajal (L.C.-F.F.), Madrid; Hospital Universitario de la Princesa (V.M.L.), Madrid; Complejo Hospitalario Universitario de Albacete, (E.F.D.); Hospital Universitario Fundación Jiménez Díaz (I.M.T.), Madrid; Hospital General Universitario Gregorio Marañón (J.M.G.-D.), Madrid; Hospital La Mancha Centro (G.O.-S., Á.D.S.), Alcázar de San Juan; Hospital Universitario Príncipe de Asturias (L.A.P.), Alcalá de Henares; Hospital Universitario Infanta Leonor (M.G.M.), Madrid; Hospital Universitario Mútua Terrasa (J.J.S.-F.); Complejo Asistencial de Ávila (A.B.C.-R.), Ávila; Hospital Universitario de Fuenlabrada (L.A.R.A.), Madrid; Hospital Universitario Son Espases, Palma de Mallorca (M.C.S.); Complejo Hospitalario de Navarra (M.A.O.-M., T.A.B.), Pamplona; Hospital Universitario y Politécnico La Fe (F.C.P.-M.), Valencia; Hospital Regional Universitario de Málaga (V.R.G.); Hospital Universitario de Getafe (J.J.B.-G.), Madrid; Hospital Santa Barbara (M.M.P.), Puertollano; Hospital Virgen de la Salud (I.P.M.), Toledo; Hospital Universitario Virgen de las Nieves (C.A.G.), Granada; Hospital Universitario Puerta del Sur (CINAC), Madrid (C.G.C.); Hospital Clínico Universitario Zaragoza (C.Í.M.), Zaragoza; Hospital Clínico Universitario Valladolid (N.T.L.,), Valladolid; Hospital Virgen del Puerto (F.C.P.), Plasencia; Hospital Universitario Donostia (T.C.T.), San Sebastian; Hospital General de Segovia (D.M.C.-S.), Segovia; Hospital General Universitario de Alicante (Á.P.S.), Alicante; Hospital Universitario Miguel Servet (IIS Aragón) (B.S.T.), Zaragoza; Hospital Universitario Araba (A.Á.A.), Vitoria; Hospital Clínico Universitario de Santiago de Compostela (E.C.A.), Santiago de Compostela; Hospital Universitario Juan Ramón Jiménez (E.D.-F.), Huelva; Hospital de Terrasa (M.F.M.), Terrasa; Hospital Universitario de Canarias (M.G.P.), San Cristobal de La Laguna; Hospital Universitario Dr Peset de Valencia (L.L.P.), Valencia; Complejo Hospitalario Universitario de Cartagena (J.M.P.), Murcia; Hospital Clínico San Carlos (C.O.-G.),Facultad de Medicina, Universidad Complutense de Madrid, IdISSC, Madrid; and CSUR Unidad de Esclerosis Múltiple y Neuroinmunología Clínica (J.E.M.-L.), Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Cátedra de Esclerosis Múltiple y Neuroinmunología Clínica, UCAM, Universidad Católica San Antonio, Murcia, Spain.
- Correspondence
Dr. J. Meca-Lallana pmecal{at}gmail.com
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti–SARS-CoV-2 AntibodiesAn Observational StudyKévin Bigaut, Laurent Kremer, Thibaut Fabacher et al.Neurology: Neuroimmunology & Neuroinflammation, July 28, 2021 -
Research Article
Autologous Hematopoietic Stem Cell Transplantation in Active Multiple SclerosisA Real-world Case SeriesRichard S. Nicholas, Elijah E. Rhone, Alice Mariottini et al.Neurology, July 12, 2021 -
Views & Reviews
COVID-19 Among Patients With Multiple SclerosisA Systematic ReviewMahdi Barzegar, Omid Mirmosayyeb, Mahsa Gajarzadeh et al.Neurology: Neuroimmunology & Neuroinflammation, May 20, 2021 -
Article
Association of Spectral-Domain OCT With Long-term Disability Worsening in Multiple SclerosisJeffrey Lambe, Kathryn C. Fitzgerald, Olwen C. Murphy et al.Neurology, March 02, 2021